Blue Light for Treating Eczema

Not Applicable

Completed

• Conditions: Eczema
• Interventions: Device: PSO-CT02 device

• Registration Number: NCT02002871
• Lead Sponsor: Philips Electronics Nederland BV

Brief Summary

Monocenter, randomized, intraindividual, open label, exploratory study comparing 4 weeks of treatment with 453nm blue light with no treatment in patients with Eczema. Patients will be screened up to 28 days before start of treatment. During the screening visit, the purpose and procedures of the study will be explained to potential patients and informed consent will be obtained. In addition, fungal superinfection of the target area will be examined using direct preparations and mycology cultures. At the baseline visit, patients with Eczema will be determined and all inclusion and exclusion criteria will be assessed. For eligible patients, two comparable treatment areas will be randomized to treatment with blue light (target area) or to serve as untreated control area. After randomization, patients will receive treatment of the target area with 3 applications per week at the investigational site for a total treatment period of 4 weeks. During those 4 weeks, safety and effectiveness assessments will be performed at weekly intervals. After end of treatment, the patients will be followed-up for another 2 weeks. In case no full resolution of adverse events occurred at the 2 week follow-up visit, a follow-up call will be performed after another 2 weeks. Treatment responses will be photo documented

Detailed Description

Not available

Study Timeline

• Study Start: 2013-10
• Study First Submitted: 2013-12-02
• Study First Submitted QC: 2013-12-02
• Study First Posted: 2013-12-06
• Primary Completion: 2014-03
• Study Completion: 2014-03
• Results First Submitted: 2015-03-16
• Status Verified: 2015-06
• Results First Submitted QC: 2015-06-24
• Last Update Submitted: 2015-06-24
• Results First Posted: 2015-07-20
• Last Update Posted: 2015-07-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 21

Inclusion Criteria

1. Signed and dated informed consent prior to any study-mandated procedure

2. Good health as determined by the Investigator according to physical examination

3. Willing and able to comply with study requirements

4. Skin type I-IV according to Fitzpatrick

5. Eczema, severity defined by an Eczema Area Severity Index (EASI)smaller/equal 20

6. Comparable clinical symptomatology of both intended treatment Areas

7. Reliable method of contraception for women of childbearing potential (i.e. low failure rate less than 1% per year; e.g. oral contraceptives, intrauterine device [IUD] or transdermal contraceptive patch) 9. Willing to abstain from excessive sun / UV exposure (e.g. sunbathe, solarium) during the course of the study

Exclusion Criteria

1. Inmates of psychiatric wards, prisons, or other state institutions
2. Investigator or any other team member involved in the conduct of the clinical study
3. Participation in another clinical trial within the last 30 days
4. Pregnant and lactating women
5. Photodermatosis and/or Photosensitivity
6. Porphyria and/or hypersensitivity to porphyrins
7. Congenital or acquired immunodeficiency
8. Patients with any of the following conditions present on the study areas; Malignoma of the skin or severe actinic damage of the skin, atypical naevi or signs of hyperpigmentation, precancerosis viral (e.g. herpes or varicella) lesions of the skin, fungal and bacterial skin infections, parasitic infections and atrophic skin
9. Patients with genetic deficiencies attached with increased sensitivity to light or increased risk to dermatologic cancer (i.e. Xeroderma pigmentosum, Cockayne Syndrome, Bloom- Syndrome)
10. Current diagnosis of exfoliative or toxic dermatitis.
11. Evidence of superinfection of the intended treatment areas

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Blue light	PSO-CT02 device	Irradiation with PSOCT02 device emitting blue light at a wavelength of 453nm

Primary Outcome Measures

Name	Time	Method
Change From Baseline (Visit 2) of the Sum Score of Local Eczema Rating of the Target Area as Compared to the Control Area at End of Treatment	at week 4	The investigator rated the key symptoms erythema, induration/papulation/edema, excoriation, lichenification and crusts on a score of 0-3 (none, mild, moderate, and severe) with half steps allowed. A total severity score was calculated as the sum of the single symptom ratings (range 0-15 whereas 0 (best) - 15 (worst)).

Secondary Outcome Measures

Name	Time	Method
Change From Week 4 (End of Treatment) of Inflammation (Erythema) Evaluated by Mexameter of the Target Area as Compared to the Control Area at End of Follow-up	week 6	Higher values describe a higher level of erythema.
Change From Baseline of Patient Rating of Itching of the Target Area as Compared to the Control Area	week 4, 6	patients were asked to rate itching on a VAS scale (1 no itching; 100 worst imaginable itching)
Change From Baseline of Inflammation (Erythema) Evaluated by Mexameter of the Target Area as Compared to the Control Area	week 4, 6	Higher values describe higher erythema levels.
Change From Week 4 of the Sum Score of Local Eczema Rating as Compared to the Control Area at End of Follow-up	week 6	The investigator rated the key symptoms erythema, induration/papulation/edema, excoriation, lichenification and crusts on a score of 0-3 (none, mild, moderate, and severe) with half steps allowed. A total severity score was calculated as the sum of the single symptom ratings (range 0-15 whereas 0 (best) - 15 (worst)).
Change From Week 4 (End of Treatment) of Patient Rating of Itching of the Target Area as Compared to the Control Area at End of Follow-up	week 6	patients were asked to rate itching on a VAS scale (1 no itching; 100 worst imaginable itching).

Trial Locations

Locations (1)

Klinik for Dermatology and Allergology, medical faculty of the RWTH Aachen; 🇩🇪 Aachen, NRW, Germany